Search research articles
Contact Us
Filters
Showing results (171-180 of 186) with videos related to
Page
of 19
Sort By:
The American Journal of Cardiology
|
December 14, 2001
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention
M T Roe, C B Granger, J A Puma, et al.
Journal of the American College of Cardiology
|
February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial
Hitinder S Gurm, A Michael Lincoff, David Lee, et al.
JAMA
|
January 27, 2000
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
J H Alexander, R A Sparapani, K W Mahaffey, et al.
The American Journal of Cardiology
|
June 27, 2000
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial)
A Barbagelata, R M Califf, E B Sgarbossa, et al.
Circulation
|
September 7, 2000
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
M T Roe, R A Harrington, D M Prosper, et al.
Journal of the American College of Cardiology
|
February 24, 2001
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators
A B Greenbaum, R A Harrington, M P Hudson, et al.
Circulation
|
September 7, 2000
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial
A M Lincoff, R A Harrington, R M Califf, et al.
American Heart Journal
|
April 27, 2000
Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts
G W Barsness, C Buller, E M Ohman, et al.
Lancet (London, England)
|
April 12, 2001
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
H D Aronow, E J Topol, M T Roe, et al.
Heart (British Cardiac Society)
|
March 12, 2008
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
R D Lopes, K S Pieper, J R Horton, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 186) with videos related to
Sort By:
Page
of 19
The American Journal of Cardiology
|
December 14, 2001
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention
M T Roe, C B Granger, J A Puma, et al.
Journal of the American College of Cardiology
|
February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial
Hitinder S Gurm, A Michael Lincoff, David Lee, et al.
JAMA
|
January 27, 2000
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
J H Alexander, R A Sparapani, K W Mahaffey, et al.
The American Journal of Cardiology
|
June 27, 2000
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial)
A Barbagelata, R M Califf, E B Sgarbossa, et al.
Circulation
|
September 7, 2000
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
M T Roe, R A Harrington, D M Prosper, et al.
Journal of the American College of Cardiology
|
February 24, 2001
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators
A B Greenbaum, R A Harrington, M P Hudson, et al.
Circulation
|
September 7, 2000
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial
A M Lincoff, R A Harrington, R M Califf, et al.
American Heart Journal
|
April 27, 2000
Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts
G W Barsness, C Buller, E M Ohman, et al.
Lancet (London, England)
|
April 12, 2001
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
H D Aronow, E J Topol, M T Roe, et al.
Heart (British Cardiac Society)
|
March 12, 2008
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
R D Lopes, K S Pieper, J R Horton, et al.
Page
of 19